How often does clozapine monitoring prevent fatal myocarditis?

Clozapine monitoring has never been tested in a trial designed to show it prevents fatal myocarditis. The evidence is all indirect.

The retrieved studies describe the problem, not the solution. One review puts clozapine myocarditis incidence at 0.7% to 1.2% of treated patients, with over 85% of cases in the first two months [1, 2]. Another reports that subclinical cardiotoxicity (a drop in heart function without symptoms) may affect about one-third of patients [2]. But no study in this set compares a monitored group to an unmonitored group and counts deaths. The monitoring protocols recommended—serial CRP, troponin, BNP, echocardiogram—are based on expert opinion and case series, not on a controlled trial that proved they save lives [2, 3].

The biomarkers themselves have known limits. Troponin detects only about 35% of biopsy-confirmed myocarditis cases [1]. That means two out of three cases could be missed by troponin alone. CRP is a general inflammation marker, not specific to the heart. A normal result does not rule out myocarditis, and an elevated result does not confirm it. The monitoring protocols are a reasonable guess, not a proven safety net.

The fatal myocarditis rate is not given directly in these records, but one source notes that clozapine-associated cardiomyopathy (a related but later-stage condition) carries a mortality of 12.5% to 24% [2]. If early myocarditis is missed, it can progress to that. The monitoring is meant to catch it before it does, but the sensitivity of the screening tools is too low to guarantee that.

My call: clozapine monitoring probably catches some cases early, but the evidence does not show how often it prevents a death. The screening tools miss a substantial fraction of cases. Confidence: low.